Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphodiesterase type 5 inhibitors and kidney disease
Barış Afşar, Alberto Ortíz, Adrian Covic, et al.
International Urology and Nephrology (2015) Vol. 47, Iss. 9, pp. 1521-1528
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

The next generation of therapeutics for chronic kidney disease
Matthew D. Breyer, Katalin Suszták
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 8, pp. 568-588
Open Access | Times Cited: 251
New progress in drugs treatment of diabetic kidney disease
Junmin Wang, Hongjiao Xiang, Yifei Lü, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111918-111918
Open Access | Times Cited: 56
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
Ahmed K. ElHady, Dalia S. El‐Gamil, Mohammad Abdel‐Halim, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1266-1266
Open Access | Times Cited: 24
Targeting inflammation in diabetic kidney disease: early clinical trials
María Vanessa Pérez-Gómez, María Dolores Sánchez-Niño, Ana B. Sanz, et al.
Expert Opinion on Investigational Drugs (2016) Vol. 25, Iss. 9, pp. 1045-1058
Closed Access | Times Cited: 73
Kidney dysfunction in patients with pulmonary arterial hypertension
Nils Nickel, Joanne M. O’Leary, Evan L. Brittain, et al.
Pulmonary Circulation (2016) Vol. 7, Iss. 1, pp. 38-54
Open Access | Times Cited: 64
Anti-fibrotic treatments: A review of clinical evidence
Marco Allinovi, Letizia De Chiara, Maria Lucia Angelotti, et al.
Matrix Biology (2018) Vol. 68-69, pp. 333-354
Open Access | Times Cited: 54
Coronary Heart Disease, Diabetes, and Sexuality in Men
Geoff Hackett, Michael Krychman, David Baldwin, et al.
The Journal of Sexual Medicine (2016) Vol. 13, Iss. 6, pp. 887-904
Closed Access | Times Cited: 53
The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS)
Raed AlRuwaili, Hayder M. Al‐kuraishy, Mubarak Alruwaili, et al.
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 5, pp. 1267-1278
Open Access | Times Cited: 15
Exploring the Multifaceted Potential of Sildenafil in Medicine
Ciprian Pușcașu, Anca Zanfirescu, Simona Negreş, et al.
Medicina (2023) Vol. 59, Iss. 12, pp. 2190-2190
Open Access | Times Cited: 13
Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review
Georgios Georgiadis, Ioannis-Erineos Zisis, Anca Oana Docea, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 5, pp. 1284-1284
Open Access | Times Cited: 37
The role of cGMP and its signaling pathways in kidney disease
Kunyu Shen, David W. Johnson, Glenda C. Gobé
AJP Renal Physiology (2016) Vol. 311, Iss. 4, pp. F671-F681
Open Access | Times Cited: 36
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
Jeong Hee Hong, Young Suk Kwon, Isaac Yi Kim
Expert Opinion on Drug Metabolism & Toxicology (2016) Vol. 13, Iss. 2, pp. 183-192
Closed Access | Times Cited: 35
Emerging therapeutics for the treatment of diabetic nephropathy
Jehrod Brenneman, Jon Hill, Steve Pullen
Bioorganic & Medicinal Chemistry Letters (2016) Vol. 26, Iss. 18, pp. 4394-4402
Closed Access | Times Cited: 31
Phosphodiesterase-5 inhibitors ameliorate structural kidney damage in a rat model of contrast-induced nephropathy
Andrei Iordache, Ana Maria Bugă, Dana Maria Albulescu, et al.
Food and Chemical Toxicology (2020) Vol. 143, pp. 111535-111535
Closed Access | Times Cited: 24
Reno-protective effects of Phosphodiesterase 5 inhibitors
Enis Rauf Coşkuner, Burak Özkan
Clinical and Experimental Nephrology (2021) Vol. 25, Iss. 6, pp. 585-597
Closed Access | Times Cited: 18
Pulmonary hypertension in end-stage renal disease
Joe Devasahayam, Tony Oliver, Valentina Joseph, et al.
Respiratory Medicine (2020) Vol. 164, pp. 105905-105905
Open Access | Times Cited: 20
Local cyclic adenosine monophosphate signalling cascades—Roles and targets in chronic kidney disease
Anastasiia Sholokh, Enno Klußmann
Acta Physiologica (2021) Vol. 232, Iss. 1
Open Access | Times Cited: 17
Genetics of NO Deficiency
Kirsten Leineweber, Sven Moosmang, Dan Paulson
The American Journal of Cardiology (2017) Vol. 120, Iss. 8, pp. S80-S88
Open Access | Times Cited: 18
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
Geoffrey Hackett
The World Journal of Men s Health (2020) Vol. 38, Iss. 3, pp. 271-271
Open Access | Times Cited: 15
The Graham Jackson Memorial Lecture ISSM 2016—“The Man Who Knew Too Much”: Time to Recognize Erectile Dysfunction and Low Testosterone as Independent Risk Factors for Cardiovascular Disease
Geoffrey Hackett
Sexual Medicine Reviews (2017) Vol. 5, Iss. 3, pp. 256-265
Closed Access | Times Cited: 13
Renoprotective effect of local sildenafil administration in renal ischaemia–reperfusion injury: A randomised controlled canine study
Mohamed H. Zahran, Nashwa Barakat, Sherry M. Khater, et al.
Arab Journal of Urology (2019) Vol. 17, Iss. 2, pp. 150-159
Open Access | Times Cited: 13
Impaired pulmonary vasomotor control in exercising swine with multiple comorbidities
Jens van de Wouw, Jarno J. Steenhorst, Oana Sorop, et al.
Basic Research in Cardiology (2021) Vol. 116, Iss. 1
Open Access | Times Cited: 11
Cyclic Adenosine Monophosphate Signaling in Chronic Kidney Disease: Molecular Targets and Therapeutic Potentials
Charlotte Delrue, Reinhart Speeckaert, Rafael Noal Moresco, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9441-9441
Open Access | Times Cited: 1
Intervention of roasted cashew nut supplement against endothelial renal vasoconstriction disease in hypertensive rats exposed to mixed-fractionated petroleum products
J.K. Akintunde, A.O. Okunubi, Oluwatosin Adebisi Dosumu, et al.
Clinical Nutrition Open Science (2024) Vol. 58, pp. 183-205
Open Access | Times Cited: 1
Erectile dysfunction and testosterone deficiency as cardiovascular risk factors?
Geoffrey Hackett, Michael Kirby
International Journal of Clinical Practice (2018) Vol. 72, Iss. 2, pp. e13054-e13054
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top